TSK Laboratory International, a global manufacturer of premium needles and cannulas, has launched direct operations in Australia and New Zealand.

Until now, practitioners across Australia and New Zealand have relied on a network of medical wholesalers to procure TSK’s needles and cannulas, which include Steriject, the Invisible Needle, and its Low Dead Space (LDS) technology, which minimises the space within the syringe-hub assembly, preventing air bubbles and reducing waste of sight-saving biologics. The launch of direct operations effectively centralises and streamlines this supply chain through a dedicated, localised e-commerce platform.

TSK, which has based its operations in Macquarie Park, Sydney, said ophthalmic professionals will benefit from product authenticity, a more resilient supply chain, and highly transparent, competitive pricing.

EDUCATION AND SUPPORT

Beyond streamlining procurement, TSK said establishing a direct physical footprint will facilitate closer relationships with its ANZ customer base. The company plans to roll out a suite of dedicated educational resources for local practitioners and has committed to offering educational discounts to third party training institutes. This will help ophthalmologists refine advanced techniques, maximise the efficacy of TSK devices, and continue prioritising patient safety across the region.

Visit: shopaus.tsklab.com.